INTRODUCTION: Atherosclerosis is one of the inflammatory underlying disease associated by oxidative stress and thrombotic agents. This study aimed to evaluate the potential role of cupper oxidized low-density lipoprotein (OxLDL) and thrombin for inducing mitogen activated protein kinases (MAPKs) in platelets. METHODS: Phosphorylation of P38MAPK, Jun N-terminal Kinase (JNK), and Extracellular signal-regulated kinases (ERK1/2) and P-selectin expression were determined in lysates of washed human platelets pretreated with low doses of thrombin and cu2+-OxLDL By Enzyme-linked immunosorbent assay (ELISA). Pharmacological inhibition was performed by SB203580, PD980559 and SP6000125 for P38MAPK, ERK1/2 and JNK activity, respectively. The ratio of phosphorylated to total protein was used for normalizing the phospho proteins contents of cells. RESULTS: OxLDL and thrombin significantly and differentially increased P-selectin expression (P<0.05), P38MAPK (P<0.05) and c-JNK (P<0.05) and ERK1/2 (P<0.05) phosphorylation in platelets. SB 203580 and SP6000125 significantly decreased P-selectin expression in both oxidative (P<0.05) and thrombotic (P<0.05) activated platelets. CONCLUSION: Our results indicated that MAPK inhibitors can reduce atherothrombotic events via alterations in P-selectin expression suggesting that these inhibitors may be useful in the inhibition of atheroma development.
INTRODUCTION:Atherosclerosis is one of the inflammatory underlying disease associated by oxidative stress and thrombotic agents. This study aimed to evaluate the potential role of cupper oxidized low-density lipoprotein (OxLDL) and thrombin for inducing mitogen activated protein kinases (MAPKs) in platelets. METHODS: Phosphorylation of P38MAPK, Jun N-terminal Kinase (JNK), and Extracellular signal-regulated kinases (ERK1/2) and P-selectin expression were determined in lysates of washed human platelets pretreated with low doses of thrombin and cu2+-OxLDL By Enzyme-linked immunosorbent assay (ELISA). Pharmacological inhibition was performed by SB203580, PD980559 and SP6000125 for P38MAPK, ERK1/2 and JNK activity, respectively. The ratio of phosphorylated to total protein was used for normalizing the phospho proteins contents of cells. RESULTS: OxLDL and thrombin significantly and differentially increased P-selectin expression (P<0.05), P38MAPK (P<0.05) and c-JNK (P<0.05) and ERK1/2 (P<0.05) phosphorylation in platelets. SB 203580 and SP6000125 significantly decreased P-selectin expression in both oxidative (P<0.05) and thrombotic (P<0.05) activated platelets. CONCLUSION: Our results indicated that MAPK inhibitors can reduce atherothrombotic events via alterations in P-selectin expression suggesting that these inhibitors may be useful in the inhibition of atheroma development.
Authors: Y C Lim; M W Wakelin; L Henault; D J Goetz; T Yednock; C Cabañas; F Sánchez-Madrid; A H Lichtman; F W Luscinskas Journal: Microcirculation Date: 2000-06 Impact factor: 2.628
Authors: Pierre Rotzius; Sebastian Thams; Oliver Soehnlein; Ellinor Kenne; Chi-Nan Tseng; Niklas K Björkström; Karl-Johan Malmberg; Lennart Lindbom; Einar E Eriksson Journal: Am J Pathol Date: 2010-05-14 Impact factor: 4.307
Authors: Sybille Rex; Lea M Beaulieu; David H Perlman; Olga Vitseva; Price S Blair; Mark E McComb; Catherine E Costello; Jane E Freedman Journal: Thromb Haemost Date: 2009-07 Impact factor: 5.249